American Journal of Transplantation· 2012Q1
Three-Year Outcomes From BENEFIT-EXT: A Phase III Study of Belatacept Versus Cyclosporine in Recipients of Extended Criteria Donor Kidneys
- 263citations
- Q1SCImago
- 2012year
Short summary
Belatacept treatment led to a 11 mL/min higher mean GFR compared to cyclosporine in recipients of extended criteria donor kidneys after 3 years, with similar graft survival (80-82%) and acute rejection rates.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Transplantation
TransplantationMedicine